How Much Do Weight Loss Injections Cost?

Updated on September 20, 2026 | Written by Alec Pow
This article was researched using 14 sources. See our methodology and corrections policy.

Weight loss injections in the United States can cost from about $299 to $449 per month through current manufacturer self-pay pricing for common Zepbound doses, while standard Wegovy pen pricing is $349 per month. Brand list prices can still exceed $1,300 per month. Insurance can move the bill lower or higher, and eligible Medicare beneficiaries can pay $50 per month for certain covered GLP-1 weight-management drugs through a temporary federal program.

The real bill can combine the injection, insurance rules, manufacturer cash programs, provider care, membership charges, and lab work. Wegovy, Zepbound, Saxenda, and generic liraglutide also use different price structures, so a single national average hides too much.

Article Highlights

• Wegovy pens have a current list price of $1,349.02 (at $30 per hour, earning that amount would take about 1.1 full-time workweeks, before taxes) per package, while the standard manufacturer self-pay price for common injection strengths is $349 per month.
• Zepbound KwikPen self-pay prices start at $299 per month for 2.5 mg and $399 per month for 5 mg.
• Higher Zepbound doses can qualify for a $449 per month refill offer under current program terms.
• Saxenda has a list price of $1,349.02, while FDA-approved generic liraglutide for weight management now gives patients another pharmacy-price path.
• Eligible Medicare Part D beneficiaries can pay $50 per month for covered drugs through the Medicare GLP-1 Bridge through December 31, 2027.
• Telehealth membership fees can add hundreds or more than $1,000 per year on top of the drug price.

How Much Do Weight Loss Injections Cost?

For a reader paying cash in 2026, the most useful starting range for major FDA-approved weight-management injections is about $299 to $449 (about 1.2 to 1.9 full-time workdays at $30 per hour) per month through manufacturer self-pay channels for many Wegovy and Zepbound prescriptions. Higher regular Zepbound dose prices can reach $699 per month, and brand list prices can sit above $1,300. The pharmacy charge can differ because insurance, savings-card rules, dose, product form, pharmacy, and eligibility all matter.

The table separates list price from current self-pay pricing. Wegovy uses a fixed standard cash price across several pen strengths, while Zepbound uses dose-based prices and a refill-linked purchase offer for higher doses.

Why List Price Can Mislead

List price is the manufacturer’s published benchmark before rebates, insurance payments, savings programs, and some negotiated discounts. It is useful for comparing sticker prices, but it is not the same thing as a guaranteed pharmacy bill. Wegovy makes the gap easy to see. Its current list price is $1,349.02 (about 1.1 full-time workweeks at $30 per hour) per package, while the standard self-pay price for the 0.25 mg through 2.4 mg pens is $349 per month.

Using those two published figures, 12 months at list price would equal $16,188.24, while 12 months at the standard $349 self-pay price would equal $4,188. The difference is $12,000.24 per year, or about 74% below the list-price calculation. This calculation is a price comparison, not a forecast for one patient. Insurance, another offer, a treatment change, or fewer than 12 fills can alter the result.

For budgeting, compare the same type of price across products. A list price belongs next to another list price, while a manufacturer cash offer belongs next to another cash offer. Mixing those categories can make one drug look far more expensive even when the payable cash difference is much smaller.

Wegovy Price

Wegovy is semaglutide sold for chronic weight management under its own FDA-approved indications. The standard injection is taken weekly. Current self-pay pricing for 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg pens is $349 per month. New patients who meet the offer terms can pay $199 for each of the first two monthly fills at 0.25 mg and 0.5 mg through December 31, 2026. Wegovy HD 7.2 mg is priced at $399 per month through the same cash channel.

The higher-dose product is new. The FDA approved Wegovy HD in March 2026, so older articles that call 2.4 mg the highest Wegovy injection strength are now stale. The FDA Wegovy HD approval states that 7.2 mg is an approved higher-dose semaglutide injection for certain adults using Wegovy for long-term weight reduction and maintenance.

Commercial insurance can create another price. Novo Nordisk’s current Wegovy savings offer says eligible commercially insured patients may pay as little as $25 per month, subject to the program’s savings limit and restrictions. Government beneficiaries are excluded from that commercial offer. Anyone comparing Wegovy with a telehealth service should also separate the drug charge from any recurring care membership.

Zepbound Price

Zepbound uses tirzepatide and is supplied as a once-weekly weight-management injection. Its published self-pay schedule changes by dose, so the starter price should not be treated as the long-run price for every prescription. The prescribed dose and eligibility for the refill offer can change the monthly cash bill.

Current Zepbound KwikPen regular self-pay prices are $299 per month for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, and $699 for 10 mg, 12.5 mg, or 15 mg. Lilly’s current purchase program can price 7.5 mg through 15 mg at $449 per month if the refill rules are met. The published terms require the next purchase within 45 days of the prior delivery or receipt for the offer to continue.

That refill condition has a measurable value. At 10 mg through 15 mg, the difference between the regular $699 cash price and the $449 program price is $250 per fill. Twelve qualifying fills at the lower figure would be $5,388 versus $8,388 at the regular price, a difference of $3,000. This calculation assumes the same qualifying higher dose for all 12 fills and does not describe a dosing plan.

Saxenda and Generic Liraglutide

Saxenda remains part of the weight-loss injection market, but it differs from Wegovy and Zepbound because liraglutide is injected daily rather than weekly. Novo Nordisk lists Saxenda at $1,349.02 for the brand product. The company’s published Saxenda list price also notes that insured patients can have a different out-of-pocket amount and that eligibility rules apply to manufacturer savings.

The larger 2026 change is generic competition. FDA generic approval records show that Teva received approval in August 2025 for liraglutide injection referencing Saxenda for chronic weight management. That means an older claim that Saxenda has no generic alternative is no longer accurate. FDA approval does not create one national cash price because pharmacy inventory, quantity, discount contracts, and insurance terms can differ.

Recent pharmacy-discount data put generic liraglutide prices near $121.50 to $307.59 per 3 mL pen at several major chains before the site’s coupon price is applied. One pen is not the same thing as a full month at the maximum weight-management dose, so multiplying a one-pen quote into a treatment budget requires the prescribed daily dose and quantity. That unit mismatch is one reason some very low generic prices online can look cheaper than the amount needed for a full monthly prescription.

Insurance and Medicare

Private insurance does not use one national GLP-1 benefit. A plan can cover an obesity medication, exclude it, place it behind prior authorization, or require cost sharing tied to the plan’s formulary and deductible. Manufacturer savings cards may lower the amount for some commercially insured patients, but the terms differ by product. A low advertised copay should be read as an eligibility-based offer rather than the normal price for every insured person.

Medicare changed materially on July 1, 2026. The federal GLP-1 Bridge program gives eligible Medicare Part D beneficiaries access to covered Wegovy forms and the Zepbound KwikPen for a $50 monthly copay. The demonstration runs through December 31, 2027. CMS states that the $50 payment does not count toward the Part D deductible or true out-of-pocket spending, and the program has its own clinical eligibility and prior-authorization rules.

Coverage outside Medicare still needs a plan-specific check because employer and individual-market formularies differ. The Bridge operates outside the normal Part D payment flow and carries the same $50 per month beneficiary charge for those who qualify. Patients should compare the plan’s pharmacy benefit with cash pricing before assuming insurance is the lower-cost route.

Hidden Costs

The medication can be only one line of the bill. A primary-care or obesity-medicine visit may be billed through insurance or paid directly. A telehealth platform may add a recurring membership for clinician access, messaging, refill management, coaching, or insurance support. Lab work can also be billed outside the drug price when a clinician orders it and it is not included in the care program.

Ro gives a current public example of the membership effect. Its weight-loss membership pricing is $39 for the first month and $149 per month on the flexible monthly plan after that, with medication billed separately. Eleven renewal months plus the first month equal $1,678 in first-year membership charges before medication. Pair that illustrative membership schedule with 12 months of Wegovy at its standard $349 self-pay price and the combined total becomes $5,866. The care membership adds about 40% to the drug-only $4,188 calculation.

A reader comparing telehealth programs can use current ThePricer pages on WeightWatchers medical care, Found weight-loss pricing, and Hims membership costs to separate the care fee from the prescription. The cheapest advertised drug price can lose its advantage when a required membership, prepaid term, or excluded service is added.

Long-Term Treatments

Wegovy and Zepbound are approved for chronic weight management, so a treatment budget may extend beyond six or 12 months when a clinician keeps a patient on therapy. A 12-month figure is useful for household planning, but it is not a medical stop date. Starting, changing, or stopping a prescription belongs with the treating clinician.

Compounded products also need a separate price category. A clinic may advertise compounded semaglutide or tirzepatide below branded cash prices, but compounded drugs are not FDA-approved products. The FDA’s unapproved GLP-1 warning reports safety concerns involving compounded semaglutide and tirzepatide. A compounded quote is not the same price category as an FDA-approved Wegovy or Zepbound prescription.

Makes sense if

• You compare the drug, care, and insurance cost for the same prescribed product.
• You can verify whether a manufacturer cash program applies to your dose and insurance status.
• You want a 12-month budget separating medication from care fees.
• You recheck the price after a dose, plan, pharmacy, or offer change.

Does not make sense if

• You treat a brand list price and a discounted cash offer as the same price type.
• You compare a one-pen liraglutide quote with a full-month supply.
• You treat Ozempic or Mounjaro pricing as interchangeable with the obesity-labeled brands.
• You choose a medication or dose from price alone.

Answers to Common Questions

How much are weight loss injections without insurance?

Current manufacturer self-pay pricing puts many Wegovy and Zepbound prescriptions near $299 to $449 per month. Higher dose prices exist, while Saxenda carries a $1,349.02 brand list price. Generic liraglutide pricing varies by quantity and pharmacy.

How much is Wegovy per month in 2026?

Wegovy 0.25 mg through 2.4 mg pens are $349 per month at the standard self-pay price. Wegovy HD is $399 per month. Eligible new patients can get the first two lower-dose fills for $199 each under the current offer.

How much is Zepbound without insurance?

KwikPen regular self-pay pricing starts at $299 per month for 2.5 mg and rises by dose. Qualifying 7.5 mg through 15 mg refills can be $449 per month under current purchase-program rules.

Does Medicare cover weight loss injections?

Eligible Medicare Part D beneficiaries can receive covered Wegovy forms or Zepbound KwikPen through the GLP-1 Bridge for a $50 monthly copay. The program runs through December 31, 2027 and has clinical eligibility and prior-authorization rules.

Is there a generic weight loss injection?

Yes. The FDA approved liraglutide injection referencing Saxenda for weight management in August 2025. Pharmacy prices vary, and a per-pen quote is not automatically a full-month price.